The objective was to determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates development of bovine embryos. In each experiment, oocytes were fertilized in vitro, GM-CSF was added to embryo culture medium at 8-10 h or 5 days after insemination, and development was monitored as the proportion of oocytes that formed blastocysts. Addition of recombinant bovine GM-CSF to serum-free medium at 8-10 h after insemination increased the percentage of oocytes that formed blastocysts (7.2% and 15.2% for control and GM-CSF, respectively). GM-CSF did not affect cleavage rate. Rather, the effect of GM-CSF seems to be exerted after Day 5 after insemination, as indicated by the following findings: 1) GM-CSF did not alter embryo cell number at Day 5 after insemination; 2) administration of GM-CSF at Day 5 increased the proportion of oocytes that developed to the blastocyst stage (6.7%, 13.0%, and 22.4% for control and 1 and 10 ng/ml GM-CSF, respectively); and 3) addition of serum at Day 5 increased development but prevented a further increase due to addition of GM-CSF at 10 h after insemination. Blastocysts from GM-CSF-treated cultures tended to be at earlier stages of morphological development (i.e., fewer blastocysts expanded at Day 7 and fewer were hatching or hatched at Day 9 after insemination). GM-CSF may play a role in the early development of bovine embryos and might be a useful molecule for increasing blastocyst production rates in serum-free culture systems.
INTRODUCTION
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic regulatory molecule originally identified as a product of activated T lymphocytes involved in the proliferation and differentiation of hematopoietic cells [1] . In fact, GM-CSF is produced by a diverse array of cells including T lymphocytes, monocytes, macrophages, fibroblasts, and endothelial cells [1, 2] . In the human, GM-CSF or its mRNA has been identified in endometrial epithelial cells [3] , endometrial lymphocytes [4, 5] , and trophoblast [5, 6] . GM-CSF has also been localized to endometrial epithelial cells in sheep [7] and mice [8] . Uterine GM-CSF activity is elevated after mating in mice [9] .
One site of GM-CSF action appears to be trophoblast. Receptors for GM-CSF have been reported on human trophoblast [10, 11] . Also, GM-CSF increased [ 3 H]thymidine incorporation and expression of nuclear proliferation antigen by cultured human trophoblast [10] and [ 3 H]thymidine incorporation (although not cell number) by cultured murine trophoblast [12] . Moreover, i.p. injections of GM-CSF reversed high resorption rates and increased fetal and placental weights in abortion-prone mice [13] . GM-CSF has also been reported to cause morphological differentiation of human cytotrophoblast [14] . There are mixed reports as to whether GM-CSF can stimulate chorionic gonadotropin secretion from human trophoblast [14, 15] and interferon (IFN)-T secretion from sheep trophoblast [7, 16] .
It is not known whether GM-CSF regulates preimplantation embryonic development. Clearly, the preimplantation embryo is dependent upon reproductive tract-derived regulatory molecules because uterine-embryo asynchrony [17] and premature elevations in circulating progesterone concentrations [18] can affect the time course of development. Also, oviductal coculture can promote development of cultured embryos [19] , and exposure to a uterine environment is required for optimal IFN-T secretion [20] . A variety of growth factors and regulatory molecules have been reported to affect development of preimplantation embryos. In the cow, these molecules include leukemia inhibitory factor [21] , epidermal growth factor [22] , platelet-derived growth factor [23] , and the combination of transforming growth factor-3 and basic fibroblast growth factor [24] . Whether GM-CSF also participates in regulation of embryonic growth is unclear. While possible effects of GM-CSF on trophoblast proliferation [10] [11] [12] suggest that it may be involved, there was no effect of GM-CSF on growth of mouse blastocysts [25] . The objectives of the current series of experiments were to determine whether GM-CSF increases development of bovine in vitro-produced embryos, to evaluate whether effects occur before or after Day 5 after insemination, and to test whether changes in blastocyst development rates are associated with changes in blastocyst morphology.
MATERIALS AND METHODS

Materials
Recombinant bovine GM-CSF was donated by CIBA-GEIGY (Basle, Switzerland). Estradiol, heparin, HEPES, mineral oil, sodium pyruvate, and antibiotics were purchased from Sigma Chemical Company (St. Louis, MO). Bovine steer serum and heat-treated fetal calf serum were purchased from Pel-Freez (Rogers, AR) and Atlanta Biologicals (Norcross, GA), respectively. Modified Tyrode's albumin-lactate-pyruvate (TALP) solutions [26] were purchased from Specialty Media (Lavallette, NJ) and were used to prepare HEPES-TALP, in vitro fertilization (IVF)-TALP, and Sperm-TALP. The source of BSA for these media was Sigma Fraction V or Sigma essentially fatty-acid free (IVF-TALP only). Frozen semen from various bulls was obtained from American Breeders Service (Madison, WI) or Southeast Semen (Lake City, FL). CRlaa medium (containing 3 mg/ml fraction V BSA from Sigma) was prepared as described by Rosenkrans and First [27] . Pituitaryderived FSH (FSH-P) was purchased from Schering (Kenilworth, NJ). Hoechst 33342 dye was purchased from Sigma. Percoll was obtained from Pharmacia (Piscataway, NJ).
Other reagents were purchased from Fisher (Pittsburgh, PA) or Sigma.
In Vitro Production of Embryos
Oocyte recovery and in vitro maturation. Ovaries were obtained from a local abattoir. Cumulus-oocyte complexes (COCs) were obtained by aspiration of 2-to 6-mm follicles (experiment 1) or by slicing the ovary (other experiments). Oocytes completely surrounded by cumulus cells were used; they were washed three times in Tissue Culture Medium 199 (TCM-199) supplemented with 2% (v:v) steer serum, 100 U/ml penicillin G, 100 pxg/ml streptomycin, and 0.04 USP U/ml heparin. COCs (n = 10) were transferred in groups to 50-1I microdrops of oocyte maturation medium (TCM-199 with Earle's salts and supplemented with 10% [v:v] steer serum, 22 gig/ml pyruvate, 20 pig/ml FSH-P, 2 ig/ml estradiol, and 50 Rg/ml gentamicin) covered with mineral oil. Oocytes were matured for 22 h at 39C in a atmosphere of 5% CO 2 in humidified air.
Preparation of sperm. Motile spermatozoa were obtained by centrifugation of frozen-thawed semen on a 45%/90% Percoll gradient [28] . The sperm pellet at the bottom of the tube was collected, and sperm were resuspended in Sperm-TALP. Spermatozoa were centrifuged again at 1000 x g for 5 min at room temperature and resuspended in IVF-TALP to give an approximate concentration of 25 million spermatozoa/ml.
IVE After maturation, COCs were washed one time in HEPES-TALP and transferred (n = 30) to 600 I1l IVF-TALP in four-well plates. Sperm (25 Il) and 25 1I of a mixture consisting of 0.5 mM penicillamine, 0.25 mM hypotaurine, and 25 gpM epinephrine in 0.9% (w:v) NaCI were added to the drops. Fertilization was allowed to proceed for 8-10 h at 39°C in 5% CO 2 in humidified air. Cumulus cells and sperm were removed by vortexing for 4 min in 50 1il HEPES-TALP, and then oocytes/zygotes were washed 2-3 times in HEPES-TALP
In vitro culture. Oocytes/embryos were cultured in 50-gil microdrops of CRlaa containing 3 mg/ml BSA and 2.5 Rg/ml gentamicin at 39°C and 5% CO 2 . There were -30 oocytes/embryos per microdrop in experiments 1-3 and -10 per microdrop in experiment 4. In some experiments, fetal calf serum (5 il/microdrop) was added at Day 5 after insemination. Embryonic development was assessed at Days 7-9 after insemination.
Determination of Cell Number
Cell number was determined using the procedure of Pursel et al. [29] . Briefly embryos were placed on a slide and covered with 0.01% (w:v) Trypan blue dye for 1 min at room temperature. Then, Trypan blue dye was removed, and Hoechst 33342 dye (10 pg/ml) was added for 5 min at 39°C. Hoechst dye was removed, and coverslips were mounted with Permount and then firmly pushed onto the slide to spread the embryo. Staining of nuclei was visualized with an epifluorescence microscope (Leitz Laborlux K; Leica, Heerbruss, Switzerland).
Experiments
Experiment 1 was conducted to determine the effect of GM-CSF on early embryonic development. After fertilization, oocytes/embryos were assigned randomly to be placed in microdrops containing 0 or 10 ng/ml GM-CSF. Development to the blastocyst stage was determined at Days 7 and 9 after insemination. The experiment was replicated on ten occasions to accumulate a total of 284-299 oocytes per treatment.
Experiment 2 was conducted to determine whether stimulatory effects of GM-CSF occur in the presence of serum. Treatments were arranged in a 2 x 2 factorial design, with main effects being those of GM-CSF (added at 8-10 h after insemination; 0 or 10 ng/ml) and serum (added at Day 5 after insemination, either 5 JI heat-treated fetal calf serum or 5 1 culture medium as a negative control). The experiment was replicated three times using a total of 80-133 oocytes per treatment.
Experiment 3 was conducted to test effects of GM-CSF when added at Day 5 after insemination. At Day 5 of culture, microdrops received either 5 1I CRlaa (negative control), 5 ,ul fetal calf serum (positive control), or 5 ,ul GM-CSF (to a final concentration of 1 or 10 ng/ml). The experiment was replicated three times to obtain 77-102 oocytes per treatment.
Experiment 4 was conducted to determine whether GM-CSF increased growth before Day 5 after insemination. After removal from fertilization wells, oocytes/embryos were assigned randomly to microdrops containing 0 or 10 ng/ml GM-CSF. Embryos were collected on Day 5 after insemination, and cell number was assessed. The experiment was replicated 2 times so as to generate 33-39 embryos of two cells or more per treatment. As a positive control, a separate group of oocytes/embryos were cultured in the same way as the embryos collected on Day 5 after insemination except that culture proceeded until Day 7, when the proportion of embryos reaching the blastocyst stage was determined. This portion of the experiment was replicated on three occasions to obtain a total of 59-61 oocytes per treatment.
Statistical Analysis
Each experiment was replicated on several different days, using one or more microdrops of oocytes per treatment on each day. Data were analyzed by least-squares analysis of variance using the General Linear Models procedure of the Statistical Analysis System (SAS) [30] . For analysis of development, each microdrop was considered to be an experimental unit, and cleavage and blastocyst development rates were calculated within each microdrop. Data were analyzed three ways. For method 1, the dependent variables were number cleaved, number of total blastocysts, number of expanded blastocysts, and number of hatched/hatching blastocysts; total number of oocytes in the replicate (for cleavage and total blastocysts) or total number of blastocysts (for expanded blastocysts and hatched/hatching blastocysts) was used as a covariate. For method 2, percentage cleaved or percentage developed (as a proportion of oocytes or blastocysts) was the dependent variable. Method 3 was similar to method 2 except that data were analyzed after arcsin transformation. Both methods 1 and 3 avoid problems of non-normality sometimes encountered with percentage data, but only method 1 avoids the nonestimable bias in percentage data associated with unequal numbers of observations. The three analyses gave very similar results. Probability values are based on method 1 while, for clarity, least-squares mean and standard errors are presented from analysis of percentage data as determined by method 2. Each experiment was analyzed with all main effects (treatment, day, or other effects as appropriate for the experiment) and interactions in the model. All main a Data are least-squares means + SEM. b n = 6 for blastocysts that were expanded and blastocysts that were hatched. c p < 0.01, control vs. GM-CSF. dp < 0.02, control vs. GM-CSF.
effects were considered fixed. For experiment 3, differences between treatments were evaluated using orthogonal contrasts. Data for cell number in experiment 4 were analyzed by 1) least-squares analysis of variance, in which embryo was considered as an experimental unit and 2) by CATMOD [30] to test whether treatment affected the distribution of embryos among various cell number categories ( 4, 5-8, 9-16, 17-32, and > 32).
RESULTS
Experiment 1
GM-CSF had no effect on cleavage rates (Table 1) . However, addition of 10 ng/ml GM-CSF to culture medium increased the percentage of oocytes that developed to the blastocyst stage at Days 7 (p < 0.01) and 9 (p < 0.02) ( Table 1) . While not significant, there was a tendency for GM-CSF to reduce the proportion of blastocysts that had When present, GM-CSF was added 8-10 h after insemination, whereas fetal calf serum was added at Day 5 after insemination. Results are least-squares means SEM from three replicates using a total of 80-133 oocytes. In the absence of serum, GM-CSF increased the proportion of oocytes developing to blastocysts at Day 7 and Day 9 (p < 0.05). When effects of serum were included in the model, serum effects were significant at Day 7 (p < 0.05), effects of GM-CSF were not significant, and there was a tendency for an interaction between serum (+ and -) and GM-CSF (+ and -) at Day 9 (p = 0.11).
reached the expanded stage at Day 7 and that had reached the hatching or hatched stage at Day 9.
Experiment 2
Cleavage rates were similar between treatments: depending upon treatment, least-squares means ranged from 74.7% to 79.1% (pooled SEM = 1.4%). In the absence of serum, GM-CSF increased the proportion of oocytes developing to blastocyst at Day 7 and Day 9 (p < 0.05) (Fig. 1) . When effects of serum were included in the model, serum effects were significant at Day 7 (p < 0.05), effects of GM-CSF were not significant, and there was a tendency for an interaction between serum and GM-CSF at Day 9 (p = 0.11). The proportion of blastocysts that were expanded and hatched was not recorded in this experiment.
Experiment 3
Results of experiment 3 are presented in Table 2 . When added at Day 5 after insemination, 1 or 10 ng/ml GM-CSF increased the percentage of oocytes that developed to the blastocyst stage at Day 7 after insemination as compared with the control group (p < 0.05). The effect of GM-CSF was dose-dependent, with 10 ng/ml GM-CSF causing a larger increase in development to the blastocyst stage than 1 ng/ml (p = 0.06). The proportion of blastocysts at Day 7 that were expanded tended (p = 0.08) to be lower for the GM-CSF-treated groups. The effect of GM-CSF on the proportion of oocytes developing to the blastocyst stage was not significant at Day 9 after insemination, although the percentage of blastocysts was higher for GM-CSF-treated groups. The proportion of blastocysts at Day 9 that were either hatching or hatched was lower (p < 0.04) for GM-CSF-treated embryos than for control embryos.
Supplementation with serum at Day 5 after insemination increased the percentage of oocytes that developed to the blastocyst stage at Days 7 (p < 0.001) and 9 (p < 0.02) after insemination as compared to control and GM-CSF treatments. Like GM-CSF, serum tended to decrease the proportion of blastocysts that were expanded at Day 7 and that were either hatched or hatching at Day 9, but effects were not significant.
Experiment 4
Adding GM-CSF at 8-10 h after insemination did not cause a significant change in embryo cell number at Day 5 after insemination. This was true whether cell number was evaluated for embryos with two or more cells (20.2 3.1 and 21.8 ± 2.9 cells for control and GM-CSF, respectively) or only embryos with more than 10 cells (22.9 + 3.6 and 29. 6 3.7 cells for control and GM-CSF, respectively). Additionally, the distribution of embryos among various cell number classes was not affected by treatment with GM-CSF (Fig. 2) . Of embryos with more than 1 cell, the proportion that developed past the 8-cell stage was 75.6% for controls and 56.4% for those treated with GM-CSE As a positive control, some embryos were cultured under identical conditions as the ones in which cell number was determined on Day 5 after insemination except that development was allowed to proceed until Day 7. The proportion of oocytes developing to the blastocyst stage was higher (p < 0.01) for those cultured with GM-CSF (24.2%) than for control oocytes (6.1%).
GM-CSF
DISCUSSION
The results reported in this study demonstrate that GM-CSF increases the percentage of oocytes that develop to the blastocyst stage in vitro. GM-CSF does not affect cleavage rates or proportion of embryos that go through the 8-cell block since there was no beneficial effect of GM-CSF on cleavage rate, cell number at Day 5 after insemination, or the proportion of embryos developing past the 8-cell stage by Day 5 after insemination. Rather, GM-CSF probably exerts its actions at the morula stage or later, i.e., when the embryo is in the uterus. This is indicated because GM-CSF increased the blastocyst yield when added at Day 5 after insemination (when embryos have reached the morula stage), and because addition of serum at Day 5 after insemination, while stimulatory, prevented additional stimulatory effects of GM-CSE Thus, it is possible that GM-CSF regulates expression of key genes involved in morulation or blastocyst formation such as E-cadherin or Na+/ K + ATPase [31, 32] . There was a tendency for blastocysts from GM-CSF-treated cultures to be less advanced in development (i.e., a smaller proportion of expanded blastocysts at Day 7 and a smaller proportion of hatched and hatching blastocysts at Day 9). This phenomenon indicates that GM-CSF may allow more developmentally delayed embryos to undergo blastocoel formation. Perhaps GM-CSF increases blastomere proliferation so that more embryos grow to the stage at which events triggering blastulation could take place. Alternatively, GM-CSF could prevent embryonic death from occurring between Day 5 and Day 7 so that more embryos can reach the blastocyst stage of development.
The present findings suggest that GM-CSF is one of the cytokines that increase embryo development in cattle. There are an increasing number of such cytokines that have been shown to regulate embryo development. In the cow, leukemia inhibitory factor has been shown to promote early embryonic development [21] . Colony-stimulating factor-1 may be another cytokine involved in preimplantation embryonic growth in cattle: its receptor has been detected on Day 7 bovine blastocysts [33] . Greatest effects of GM-CSF on embryonic development were seen at or after Day 5 after insemination, a time when the embryo resides in the uterus. Consequentially, for GM-CSF to be a physiologically important regulator of embryonic development, it needs to be present in the uterus as a product of maternal tissues or the embryo. Immunoreactive GM-CSF has been immunolocalized to epithelium of the endometrium of the cow as well as to specific stromal cells that could represent macrophages or lymphocytes [34] . Also, GM-CSF mRNA has been localized in the luminal and glandular epithelium of the sheep endometrium [7] .
I I
Given that GM-CSF is a product of T lymphocytes and macrophages [1, 2] , it is possible that activation of specific lymphoid cell populations in the uterus by semen or conceptus antigens could increase GM-CSF production. There is some evidence for this in mice. Mating increased GM-CSF concentrations in uterine fluid, and furthermore, cultured uterine cells prepared from mated mice released more GM-CSF than did cells from unmated mice [9] . Also, supernatants of decidual cell cultures from allogeneic mouse pregnancies secreted more GM-CSF than did cultures derived from syngeneic pregnancies [35] .
Results suggest that it may be possible to use GM-CSF to increase the production of IVF-derived embryos. Nonetheless, GM-CSF was less effective than serum at increasing blastocyst yield, and the effect of GM-CSF was not additive to that of serum (indicating that serum contains factors that exert effects similar to those of GM-CSF). Thus, GM-CSF is more likely to be important for practical IVF systems only when development of defined systems without serum is envisioned. Studies need to be performed to see if pregnancy rates achieved by transfer of GM-CSFtreated embryos are similar to those of untreated embryos. The quality of blastocysts may be adversely affected by GM-CSF if one action of GM-CSF is to promote blastocyst development in retarded embryos that would otherwise not become blastocysts. Embryos developing to blastocysts later in culture have been reported to be less likely to establish pregnancy after transferred to recipients than more rapidly developing embryos [36] .
In conclusion, experiments have indicated a possible role for GM-CSF in regulation of preimplantation embryonic development in cattle. Identification of the mechanism by which GM-CSF promotes development of embryos to the blastocyst stage may provide insights into the processes by which specific developmental processes are controlled by regulatory molecules.
